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This study by Dr Thatipelli and colleagues from the Mayo
Clinic is a complex analysis that rewards careful reading and
analysis. A brief summary of their findings is important. By life table
analysis, abnormal ankle brachial index (ABI) was associated with
higher rates of both cardiovascular morbidity (CVM) (P.02) and
all-cause mortality (ACM) (P  .001). Positive dobutamine stress
echocardiography (DSE) (inducible wall motion abnormality) was
not associated with increased rates of either CVM or ACM, while
abnormal DSE (either inducible or fixed wall motion abnormality)
was associated with a trend toward a higher CVM (P .052), and
with higher ACM (P  .02). Furthermore, when tested by multi-
variate regression analysis, abnormal ABI held the strongest asso-
ciation with ACM, while neither positive nor abnormal DSE
studies were associated with significantly increased ACM. Also
coronary intervention (percutaneous transluminal coronary angio-
plasty and stenting or coronary artery bypass grafting in 69 trial
patients) did not influence the incidence of CVM or ACM. Finally,
there was no correlation between ABI and severity of induced wall
motion abnormalities.
So, what does all this mean? The authors argue plausibly that
abnormal ABI is a measure of increased total atherosclerotic bur-
den, positive DSE is a measure of the acute pathophysiologiccator of the presence of coronary atherosclerosis. Based on these
interpretations, the authors conclude that total atherosclerotic
burden and not acute pathophysiologic effects of coronary disease
best predicts prognosis. This conclusion is further supported by
their observations that abnormal but not positive DSE influenced
ACM and that coronary interventions had no influence onCVMor
ACM. They speculate that the effect of total atherosclerotic burden
on CVM and ACM is mediated by clotting system activation
associated with plaque burden.
This conclusion, if proven valid, helps to explain the benefits
of antiplatelet agents and statins as modifiers of coagulation system
activation and plaque burden accumulation respectively, and may
guide the future development of novel secondary prevention strat-
egies.
While the limitations of this study (retrospective design,
highly selected cohort, exclusions, and use of “all-cause” mortality
as an endpoint) are obvious and acknowledged by the authors,
their finding that abnormal ABI is the more accurate predictor of
CVM and ACM is important and provocative. The implications of
this finding may be far-reaching but await validation by the au-
thors’ planned prospective study correlating CT measured total
body plaque burden, clotting system activation, and prognosis.
